CA
NZ
UK
AU
IND
US
Definitive Healthcare Corp. (NASDAQ: DH) reported second-quarter earnings of $0.05 per share, surpassing the consensus estimate of $0.04 by a notable margin. Despite this positive earnings surprise, the company faced a 9% decline in revenue, decreasing to $55.2 million from $60.8 million in the …
Metagenomi Therapeutics, Inc. (NASDAQ: MGX) reported a loss of $-0.61 per share for the second quarter of 2026, significantly below the consensus estimate of $-0.53. The reportedEarningscome after a challenging first half, with MGX shares down 26.3% year-to-date and fluctuating in a 52-week range …
AbCellera Biologics Inc. (NASDAQ: ABCL) saw its shares surge 41.6% to $9.81 following the announcement of promising Phase II results for its drug ABCL635 aimed at treating moderate-to-severe hot flashes. Although the company reported a net loss of $55.4 million for Q2 2026, which …
Alamar Biosciences posted a groundbreaking 147% increase in revenue during Q2 2026, driven primarily by strong demand for its consumable products. This growth marks a significant milestone for the company, reinforcing its competitive position amid a dynamic healthcare market. The strong performance aligns with …
The earnings miss arrives amid a flurry of clinical milestones that could dictate future value, while peers VERA slipped 0.2% and VCEL and PVLA were flat.
BlossomHill Therapeutics, Inc. debuted on the public market following its IPO on August 10, 2026, successfully raising approximately $150 million by offering 9,375,000 shares at a public price of $16.00 each. ThisCapitalinfusion arises amidst a year-to-date share price decline of 0.1%. With a marketCapitalizationof …
Cogent Biosciences, Inc. (NASDAQ: COGT) has announced a plan to sell up to $400 million in shares of its common stock through an at-the-market offering initiated on August 10, 2026. This strategic move aims to bolster its financial position and support its ongoing growth …
Eli Lilly and Company (NYSE: LLY) reported an impressive second quarter, with revenue climbing 48% to $23 billion, driven largely by strongDemandfor its diabetes and obesity treatments, particularly Mounjaro and Zepbound. The company's earnings per share reached $8.38, significantly surpassing the $6.07 consensus estimate, …
The company also narrowed its net loss to $25.5 million from $27.9 million a year earlier, reflecting tighter cost discipline. The results were accompanied by clinical updates showing durable weight‑maintenance benefits from the Revita procedure, and the firm reaffirmed its cash runway into early …
Bionano Genomics outperformed revenue expectations for the second quarter, resulting in a positive movement in its share price. The latestEarnings Callrevealed a strong quarterly performance, affirming the company's growth strategy amid challenging market conditions. This development signals increasing investor confidence in Bionano's long-term viability …
Please wait processing your request...